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Replication of LCE3C–LCE3B CNV as a Risk Factor for
Psoriasis and Analysis of Interaction with Other
Genetic Risk Factors
Ulrike Hu¨ffmeier1,11, Judith G.M. Bergboer2,11, Tim Becker3, John A. Armour4, Heiko Traupe5, Xavier
Estivill6,7, Eva Riveira-Munoz6, Rotraut Mo¨ssner8, Kristian Reich9, Werner Kurrat10, Thomas F. Wienker3,
Joost Schalkwijk2, Patrick L.J.M. Zeeuwen2 and Andre´ Reis1
Recently, a deletion of two late cornified envelope (LCE) genes within the epidermal differentiation complex on
chromosome 1 was shown to be overrepresented in 1,426 psoriasis vulgaris (PsV) patients of European ancestry.
In this study, we report a confirmation of this finding in 1,354 PsV patients and 937 control individuals of German
origin. We found an allele frequency of the deletion of 70.9% in PsV patients and of 64.9% in control individuals
(w2¼ 17.44, P¼ 2.97 105, odds ratio (95% confidence interval)¼ 1.31 (1.15–1.48)). The overall copy number of
the two LCE genes had no influence on the age of onset, but we observed a dosage effect at the genotype level.
There was no evidence of statistically significant interaction with copy number of the b-defensin cluster on
8p23.1 or with an IL-23R pathway variant in a combined data set of German and Dutch individuals, whereas
evidence for interaction with the PSORS1 risk allele in German individuals was marginal and did not remain
significant after correction for multiple testing. Our study confirms the recently published finding that the
deletion of the two LCE genes is a susceptibility factor for PsV with dosage effect, while, because of power
limitation, no final conclusion regarding interaction with other PsV risk factors can be made at this stage.
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INTRODUCTION
Psoriasis vulgaris (PsV) is a common inflammatory skin
disorder characterized by epidermal hyperproliferation,
altered keratinocyte differentiation, and inflammation. An
HLA-C allele or a variant in strong linkage disequilibrium
(LD) with it is the major risk allele, especially in PsV patients
manifesting before the age of 40 years. This finding probably
corresponds to the most evidentiary psoriasis susceptibility
locus (PSORS1). Besides this risk factor and PSORS4 (see
below), replicated associations with candidate genes (RAP-
TOR and SLC12A8) have been reported so far at PSORS2 and
PSORS5 (Hewett et al., 2002; Helms et al., 2003; Capon
et al., 2004; Huffmeier et al., 2005). In addition, variants in
the IL-23R pathway have been identified by two genome-
wide association studies for PsV (Capon et al., 2007; Cargill
et al., 2007) and could be confirmed by further independent
studies (Chang et al., 2007; Nair et al., 2008, 2009;
Huffmeier et al., 2009b). Finally, copy number variation
(CNV) of a genomic segment on chromosome 8p23.1
harboring a cluster of genes encoding b-defensins (DEFB)
small antimicrobial peptides, was identified to be associated
with psoriasis in a Dutch and a German case–control cohort
(Hollox et al., 2008) and variants of the NF-kB-pathway were
recognized to be risk factors for PsV (Nair et al., 2009).
PSORS4 is a susceptibility locus on chromosome 1 initially
identified in an Italian genome-wide linkage analysis of
Italian families (Capon et al., 1999). This locus is of special
interest for PsV, because it comprises the epidermal
differentiation complex, a group of genes expressed in the
upper strata of the epidermis. Although several genes at
PSORS4—e.g., LOR, LCE1C, PGLYRP, SPRR genes, PRR9
genes, and IVL—have been suggested to account for psoriasis
susceptibility (Giardina et al., 2006; Chen et al., 2009;
Liu et al., 2008; Kainu et al., 2009), very recently, a CNV
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within the late cornified envelope (LCE) gene cluster was
identified by a genome-wide scan using pooled DNAs. The
deletion of two LCE genes (LCE3C and LCE3B) was shown to
be at higher frequency in 1,426 psoriasis patients from
several European countries than in controls and to be
associated with psoriasis in a large family-based cohort (de
Cid et al., 2009). Expression data in the same study suggested
that carriers of the deletion may have a compromised repair
response after barrier disruption of the skin (de Cid et al.,
2009). In addition, in an independent genome-wide associa-
tion study of a Chinese cohort, single-nucleotide polymorph-
isms (SNPs) in strong LD with the deletion were identified as
risk factors for psoriasis (Zhang et al., 2009).
This study investigates the contribution of LCE3C–LCE3B-
del to PsV susceptibility in German patients and also whether
this contribution to disease is independent of three other
known genetic risk factors. We, therefore, analyzed a large
case–control cohort comprising 1,354 PsV patients and 937
control individuals for the presence of LCE3C–LCE3B-del and
also genotyped three SNPs known to be in strong LD with it
(rs10888502, rs4112788, and rs4845456). In addition, we
analyzed a possible interaction between LCE3C–LCE3B-del
and other known risk factors, PSORS1 risk allele, the copy
number of the b-defensin cluster on chromosome 8p23.1 and
an SNP (rs6887695) near the IL12B gene, which represents
the strongest genetic variant of the IL-23R pathway in
German cohorts (Huffmeier et al., 2009b).
RESULTS
Genotyping of the LCE CNV as well as all SNPs fulfilled
Hardy–Weinberg equilibrium both in groups of German
patients and in control individuals. Genotyping rates were
between 94.7 and 95.6% for the three SNPs and 99.4% for
the LCE CNV. All variants except rs10888502 were in near-
perfect LD with each other, while LD was strongest between
LCE CNV and variant rs4112788, with an R2 value of 0.94.
We observed strong evidence for association of psoriasis
with LCE3C–LCE3B-del, with a significant allele frequency
difference of 6.0%, a P-value of 2.97105 and a
corresponding odds ratio (OR) of 1.31 (95% confidence
interval: 1.15–1.48) (Table 1). Association with single SNPs
was strongest for rs4112788, but also significant for the two
other SNPs at allele level (Table 2). Similar results were
obtained at haplotype level: the haplotype ‘‘GGA deletion’’
(order of variants: rs10888502—rs4112788—rs4845456—
LCE CNV) was the most common one in cases and controls
(39.4 vs 35.7%), with a corresponding P-value of 0.011
(Table 3). Even stronger was the effect of a two-marker
haplotype consisting of rs4112788 and LCE CNV: risk
haplotype ‘‘G-deletion’’ was significantly associated with a
P-value of 0.0010 (Table 3). The P-value indicating the
distribution of P-values was one order of magnitude higher in
the two-marker haplotypes analysis compared with four-
marker analysis. To determine whether the risk alleles of the
three SNPs have independent effects from the LCE CNV, we
performed a conditional analysis. Thereby, we identified
marginal evidence for the independent effects of rs4112788
(P¼0.044), but not for the other two SNPs (P-values not
significant). The P-value for rs4112788 remained not
significant after correction for multiple testing.
No significant differences in age of disease onset were
observed between the three LCE CNV genotypes. This was
also true when the analysis was restricted to patients with an
age of onset before 40 years (also known as type I psoriasis),
which represented the majority of our cases. The OR
for psoriasis patients homozygous for LCE3C–LCE3B-del
was 1.61 (1.21–2.14), which was higher than the OR
for heterozygous patients (1.16 (0.87–1.55)), indicating a
dosage effect.
As only part of the German cohort had been previously
genotyped for copy number of b-defensin cluster, we
performed a joint analysis with the Dutch study group to
Table 1. Allele and genotype frequencies (absolute number (percentage)) in 1,354 PsV patients and 937 control
probands, results of v2-statistics, and odds ratios (95% confidence intervals) for the LCE CNV
(A)
Allele CON PsV v2 P OR (95% CI)
LCE3C–LCE3B-del 1,215 (64.9) 1,899 (70.9) 17.44 2.97 105 1.31 (1.15–1.48)
Non-deletion 657 (35.1) 785 (29.2)
(B)
Genotype CON PsV v2 P OR (95% CI)1
LCE3C–LCE3B-del/LCE3C–LCE3B-del 391 (41.8) 678 (50.5)
LCE3C–LCE3B-del/non-deletion 433 (46.3) 543 (40.5) 18.010 1.228 104 1.37 (1.05–1.80)
Non-deletion/non-deletion 112 (12.0) 121 (9.0)
Abbreviations: CI, confidence interval; CNV, copy number variation; CON, control probands; LCE, late cornified envelope; LCE3C–LCE3B-del, deletion of
the two LCE genes (LCE3C and LCE3B); OR, odds ratio; PsV, psoriasis vulgaris.
1Carriers—homozygous or heterozygous—of LCE3C-LCE3B-del compared to non-carriers.
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increase the statistical power for interaction analyses. Logistic
regression analysis on data from 1,073 individuals did not
reveal any evidence for interaction (P¼0.22, Table 4). In a
combined German and Dutch case–control study consisting
of 1,567 patients and 1,272 individuals, no evidence for
interaction of the LCE3C–LCE3B–CN with rs6887695 (SNP
Table 2. Allele and genotype frequencies (absolute number (percentage)) in 1,354 PsV patients and 937 control
probands, results of v2-statistics, and odds ratios (95% confidence intervals) for the three SNPs
(A)
SNP Allele CON PsV v2 P OR (95% CI)
rs10888502 G 685 (38.6) 1,080 (42.2) 5.585 0.018 1.16 (1.03–1.31)
C 1,091 (61.4) 1,482 (57.8)
rs4112788 G 1,151 (64.7) 1,799 (69.1) 9.314 0.002 1.22 (1.07–1.39)
A 627 (35.3) 803 (30.9)
rs4845456 A 675 (37.7) 1,053 (40.8) 4.295 0.038 1.14 (1.01–1.29)
G 1,117 (62.3) 1,529 (59.2)
(B)
SNP Genotype CON PsV v2 P OR (95% CI)1
rs10888502 C/C 332 (37.4) 432 (33.7)
C/G 427 (48.1) 618 (48.2) 5.885 0.053 1.17 (0.98–1.4)
G/G 129 (14.5) 231 (18.0)
rs4112788 A/A 106 (11.9) 118 (9.1)
A/G 415 (46.7) 567 (43.6) 9.502 0.009 1.36 (1.03–1.79)
G/G 368 (41.4) 616 (47.3)
rs4845456 A/A 120 (13.4) 221 (17.1)
A/G 435 (48.5) 611 (47.3) 5.780 0.056 1.11 (0.93–1.33)
G/G 341 (38.1) 459 (35.6)
Abbreviations: CI, confidence interval; CON, control probands; OR, odds ratio; PsV, psoriasis vulgaris; SNP, single-nucleotide polymorphism.
1Carriers—homozygous or heterozygous—of the risk allele compared with non-carriers.
Table 3. Frequencies of four- and two-marker haplotypes, results of association statistics, and odds ratios (95%
confidence intervals) in 1,354 PsV patients and 937 control probands
Haplotype CON PsV P OR (95% CI)
(A) Haplotypes consist of four variants in the order rs10888502, rs4112788, rs4845456, LCE CN. P-value indicating distribution of haplotypes: 9.31105
G G A Del 35.7 39.4 0.011 1.17 (1.04–1.32)
C A G Non-Del 32.4 27.1 1.1 104 0.78 (0.68–0.88)
C A G Del 0.4 1.0 0.021 2.69 (1.17–6.18)
C G A Del 1.8 1.2 NS NA
C G G Del 26.2 27.7 NS NA
G A G Non-Del 2.6 2.1 NS NA
(B) Haplotypes consist of two variants in the order rs4112788, LCE CN. P-value indicating distribution of haplotypes: 1.80 106
G Del 64.5 69.3 0.0010 1.24 (1.10–1.41)
A Non-Del 35.0 29.2 3.4 105 0.77 (0.68–0.87)
A Del 0.5 1.5 2.7 104 3.19 (1.54–6.57)
Abbreviations: CI, confidence interval; CON, control probands; LCE, late cornified envelope; NS, not significant; NA, not applicable; OR, odds ratio; PsV,
psoriasis vulgaris.
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near the IL12B gene) was observed (P¼0.55). As we
observed significant differences in homogeneity of ORs for
the PSORS1 risk allele between both cohorts, we analyzed
the interaction of PSORS1 with other risk factors only in the
subset of 2,291 German individuals. We observed a tendency
toward interaction with LCE3C–LCE3B–CN, while the P-value
did not remain significant after correction for the number
of interaction analyses performed. Further calculations
on possible interactions revealed no significant P-values
(Table 4).
DISCUSSION
We present the first replication of LCE3C–LCE3B—del’s
association with psoriasis, which was previously reported
by de Cid et al. (2009). The frequency of the LCE3C–LCE3B-
del allele in our German case–control cohort was very similar
to that in the Dutch and US case–control samples (de Cid
et al., 2009). The single SNPs were all associated at allele
level, while effects were strongest for rs4112788. This variant
also shows strongest LD to LCE CNV, and haplotype analyses
revealed the stronger effects of a haplotype consisting of these
two variants than those of all four variants. Testing for
independence of LCE CNV and rs4112788 was inconclusive.
Currently, we cannot exclude that rs4112788 might modify
the risk at this locus, while the LCE CNV seems to be the
more plausible risk factor. Further functional studies
and maybe the upcoming meta-analysis (see below) will
hopefully elucidate the role of the two variants in the
pathogenesis of PsV.
Several independent studies (see, e.g., Gudjonsson et al.,
2002) have observed that the PSORS1 risk factor is strongly
associated with early age of disease onset. We performed a
similar analysis for LCE3C–LCE3B-del, which indicated that it
is not associated with early disease onset. But confirming the
previous results from the European study (de Cid et al., 2009),
we observed a dosage effect of the LCE3C–LCE3B-del
at genotype level.
The major risk allele for psoriasis has been found to be
epistatic to LCE3C–LCE3B-del in the subgroup of Dutch
individuals (de Cid et al., 2009), but not in the
other subgroups. We observed only marginal evidence for
interaction in the German cohorts, which remained not
significant after correcting for testing of multiple interactions
by Bonferroni. A large multicenter meta-analysis on the
possible interaction between PSORS1 risk allele and
LCE3C–LCE3B-del is underway (Riveira et al., in preparation).
The meta-analysis will provide more generalizable data
regarding this possible interaction and might show differ-
ences in various European populations. We did not observe
evidence for interaction of LCE3C–LCE3B-del with the b-
defensin CNV nor with a variant of the IL12B locus, whereas
we did not test the interaction with newly identified risk
alleles in the genes TNIP1 and TNFAIP3 (Nair et al., 2009).
Regarding possible interaction(s), we have to consider limited
power because of study size, and this limit does not allow a
final conclusion. In general, no evidence for interaction is not
a wholly unexpected finding, as interaction in Crohn’s
disease—a disease in which many more loci/risk factors
have been identified in total—has been observed for only
single risk factors (Hampe et al., 2007; Barrett et al., 2008)
and evidence for the replication of these findings is scarce.
MATERIALS AND METHODS
Study groups
The German case–control study consisted mainly of 1,114 PsV
patients and the 937 control probands, previously described in
Huffmeier et al. (2009b). A minority of the 1,354 cases were index
patients of 240 trios of a family-based cohort (Huffmeier et al.,
2009a). The studies were approved by the ethical committees of the
University of Erlangen-Nuremberg and of the University of Mu¨nster.
The Dutch case–control group consisted of 213 patients and 335
control individuals and has been described earlier (Hollox et al.,
2008). Permission for these studies was obtained from the local
medical ethics committee (Comissie Mensgebonden Onderzoek).
Written informed consent was obtained from each patient and
control proband before enrollment. The investigations were
conducted according to the Declaration of Helsinki principles.
Genotyping
Late cornified envelope variants. We genotyped the CNV in
German samples with a protocol modified from that used by de Cid
et al. (2009): a multiplex assay of two fluorescently marked PCR
products detected on an ABI3730 DNA sequencer (Applied
Biosystems, Foster City, CA). Briefly, we used 40 ng DNA and the
Amplitaq Gold polymerase (Applied Biosystems) to amplify a
breakpoint-spanning PCR product of 351 bp (F: 50-GGATACTAAG
AAGTTCTCAC-30, R: 50-GTGGTGAGAGAGGGCATCTC-30) for
deletion alleles and a second amplicon for wild-type alleles (primers
within the deleted region, product size 561 bp (F: 50-CATTAGCCTG
GAGCTTTTGC-30, R: 50-ACAAGTGATAACATTGTCAGGAGG-30).
The multiplex reaction was diluted 1:20; a volume of 5ml was
Table 4. Uncorrected results (P-values) of interaction
analyses in case–control cohorts
(A) Dutch or German individuals
LCE3C_3B-CN IL12B DEFB–CN
LCE3C_3B-CN — 0.55 0.22
IL12B 0.55 — 0.80
DEFB-CN 0.22 0.80 —
(B) German individuals
LCE3C_3B-CN PSORS1 IL12B DEFB–CN
LCE3C_3B-CN — 0.021 0.49 0.32
PSORS1 0.021 — 0.98 0.66
IL12B 0.49 0.98 — 0.56
DEFB–CN 0.32 0.66 0.56 —
Abbreviations: LCE, late cornified envelope; PSORS, psoriasis suscept-
ibility locus.
1P-value did not remain significant when corrected for number of
interaction analyses performed.
P-values for interaction of two risk factors can be found in a square, with
the corresponding risk factors above and on the left-hand side.
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analyzed using size standard LIZ600 (Applied Biosystems) on the
capillary sequencer. Genotypes passing quality control showed peak
intensities 42,000 fluorescent units, and in putative heterozygote
individuals, ratios of peak heights of LCE3C–LCE3B-del to those of
the non-deletion alleles were 40.5 and o3. To estimate the error
rate of genotyping, we performed duplicate genotyping of six 96-
well-microtitre plates. In all, 515 DNAs yielded an amplication in
both runs and were used to compare between genotypes. Within
these, 449 (87.2%) passed both quality criteria (see above) and were
concordant in both experiments. Seven DNAs (1.4%) passed quality
control in both runs, but showed divergent genotypes. We therefore
have to assume a genotyping error rate of approximately 1.4%. For
genotyping failures of the LCE CNV, we used the three primers
LCE3CF (50-TCACCCTGGAACTAGACCTCA-30), LCE3CR (50-CTCCA
ACCACTTGTTCTTCTCA-30), and LCE3CR2D (50-CATCCCAGGGA
TGCTGCATG-30) in a multiplex reaction as previously described (de
Cid et al., 2009) and performed agarose gel electrophoresis to
separate the deletion allele (199 bp) and non-deletion allele (240 bp).
Using this method, we also confirmed the genotypes of 37
individuals who had been successfully genotyped by the mainly
used method.
Single-nucleotide polymorphisms were genotyped with TaqMan
assays (Applied Biosystems) in the German study groups. In addition,
we sequenced 24 randomly selected individuals for the three
variants as described earlier (Huffmeier et al., 2009b) and could
verify their genotypes.
Genotyping of the LCE CNV in Dutch patients and controls was
performed as described in de Cid et al. (2009). rs6887695, the
variant of the IL12B gene, was successfully genotyped in Dutch
cases and controls with a genotyping rate of 96.1%.
DEFB CNV and available genotypes for interaction analyses
Copy numbers of the b-defensin cluster were determined in
subgroups of 317 German PsV patients and 305 control individuals,
as well as in 179 Dutch psoriasis patients and 272 control probands
as described by Hollox et al. (2008). The copy number of b-defensin
cluster was not available for the rest of the cohort.
For interaction analyses, we had data for the LCE copy number
variant and the IL12B variant res6887695 in all German and Dutch
individuals. For the main risk factor for psoriasis (PSORS1), we had
information on carriers/non-carriers of the HLA-Cw0602 allele in
Dutch individuals and used an estimation in German individuals as
described earlier (Huffmeier et al., 2009b).
Statistical and interaction analyses
To determine allele frequency differences between cases and
controls, we used chi-square statistics, with one degree of freedom
for comparisons of allele frequencies and two degrees of freedom for
comparisons of genotypes. For comparisons resulting in significant
statistical values, an OR with 95% confidence interval was
calculated (OR (confidence interval)). The LD between the four
variants was calculated with the software Haploview vs 4.0, Broad
Institute, Harvard, Massachusetts (Barrett et al., 2005). Haplotypes
were calculated with FAMHAP (Herold and Becker, 2009).
An unpaired t-test statistic was calculated to test whether PsV
patients carrying one or two LCE3C–LCE3B-del alleles develop
disease earlier than non-carriers/carriers of one LCE3C–LCE3B-del
allele.
To test for a dosage effect of LCE3C–LCE3B-del, logistic
regression analysis was performed using as reference homozygotes
for the LCE3C_LCE3B non-deletion allele.
To adjust for the effect of LCE3C_3B-del, we followed the logistic
regression framework described in Cordell and Clayton (2002).
Significant P-values were corrected by Monte–Carlo simulation for
three markers.
For stratification for other psoriasis risk factors, we used
genotypes of the strongest associated variant of the IL-23R pathway
(rs6887695 of IL12B gene) in the German cohort (Huffmeier et al.,
2009b). To stratify for single risk factors, carriers of the common risk
allele ‘‘G’’ of variant rs6886795 and carriers of more than four
copies of the b-defensin cluster were regarded as risk groups versus
non-risk groups.
To test whether the German and Dutch cohorts could be
combined in one logistic regression model, the Cochran–Mantel–-
Haenszel statistical analyses were performed. For LCE and IL12B
data, the test of homogeneity of the OR showed no significant
difference (P¼ 0.526 for a recessive model and P¼ 0.186 for a
dominant model), whereas it showed significant differences regard-
ing the PSORS1 risk allele.
To test for interaction, we followed the logistic regression
framework described in Cordell and Clayton (2002). Our model
contained one variable (risk/non-risk) for each potential interaction
partner and an interaction term to test for deviation from a
multiplicative model. The significance of the interaction term was
evaluated using a chi-square distribution with one degree of
freedom. Significant P-values were corrected using the Bonferroni
method, i.e., P-values were multiplied by 6 (for the number of
interaction analyses performed).
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